Table 2.

Association between obesity and risk of serious infections in biologic-treated patients with inflammatory bowel diseases, overall and by predefined strata, on univariate analysis and multivariate analysis (adjusted for age, comorbidities, disease characteristics, health care utilization, use of corticosteroids, immunomodulators, and opiates)

Subgroup analysis	Univariate analysis (unadjusted hazard ratio [95% CI])	Multivariate analysis (adjusted hazard ratio [95% CI])
Overall	1.15 (0.86–1.54)	0.74 (0.55–1.01)
Disease phenotype  Crohn's disease  Ulcerative colitis	1.17 (0.79–1.72) 1.10 (0.70–1.73)	0.71 (0.48–1.05) 0.81 (0.49–1.33)
Age  >60 yr  60 yr or less	0.79 (0.47–1.33) 1.18 (0.82–1.68)	0.54 (0.32–0.92) 0.85 (0.58–1.23)
Index biologic  TNFα antagonists  Vedolizumab	1.27 (0.93–1.74) 0.68 (0.30–1.55)	0.82 (0.59–1.14) 0.48 (0.19–1.19)
Elixhauser index  0–1  2 or more	0.45 (0.11–1.81) 0.87 (0.64–1.18)	0.42 (0.11–1.64) 0.76 (0.55–1.04)

CI, confidence interval.